William Blair Maintains Sell Rating on Ginkgo Bioworks Holdings
PorAinvest
sábado, 9 de agosto de 2025, 8:31 am ET1 min de lectura
DNA--
Revenue for the quarter fell by 11.7% to $49.60 million from a year ago, compared to analysts' expectations of $41.61 million. The company reported a quarterly loss of $60.3 million. Despite the financial setback, shares of Ginkgo Bioworks Holdings Inc have seen a significant increase, rising by 24.1% this quarter and gaining 42.2% so far this year [2].
The current analyst consensus is a Moderate Sell with an average price target of $10.00. William Blair analyst Matt Larew recently issued a Sell rating for the company, citing an average return of -8.1% and a 38.33% success rate on recommended stocks [1]. The company's market cap is $817.1M with a P/E ratio of -1.50 [1].
In the last three months, the mean earnings estimate of analysts had risen by about 5.2%, with no earnings estimate revisions in the last 30 days. The current average analyst rating on the shares is "sell," with a breakdown of recommendations including 1 "strong buy" or "buy," no "hold," and 3 "sell" or "strong sell" [2].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TX3Q8:0-ginkgo-bioworks-holdings-inc-expected-to-post-a-loss-of-1-57-a-share-earnings-preview/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U00S8:0-ginkgo-bioworks-holdings-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
Ginkgo Bioworks Holdings (DNA) received a Sell rating from William Blair analyst Matt Larew, who maintains an average return of -8.1% and a 38.33% success rate on recommended stocks. The current analyst consensus is a Moderate Sell with an average price target of $10.00. DNA's market cap is $817.1M and has a P/E ratio of -1.50.
Ginkgo Bioworks Holdings Inc (DNA) reported a quarterly adjusted loss of $1.10 per share for the period ending June 30, 2025, according to a Reuters news article [2]. This loss is higher than the same quarter last year when the company reported an EPS of $-2.80. The mean expectation of three analysts for the quarter was for a loss of $1.57 per share, with Wall Street's median 12-month price target standing at $8.00, about 68.3% below its last closing price of $13.46 [2].Revenue for the quarter fell by 11.7% to $49.60 million from a year ago, compared to analysts' expectations of $41.61 million. The company reported a quarterly loss of $60.3 million. Despite the financial setback, shares of Ginkgo Bioworks Holdings Inc have seen a significant increase, rising by 24.1% this quarter and gaining 42.2% so far this year [2].
The current analyst consensus is a Moderate Sell with an average price target of $10.00. William Blair analyst Matt Larew recently issued a Sell rating for the company, citing an average return of -8.1% and a 38.33% success rate on recommended stocks [1]. The company's market cap is $817.1M with a P/E ratio of -1.50 [1].
In the last three months, the mean earnings estimate of analysts had risen by about 5.2%, with no earnings estimate revisions in the last 30 days. The current average analyst rating on the shares is "sell," with a breakdown of recommendations including 1 "strong buy" or "buy," no "hold," and 3 "sell" or "strong sell" [2].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TX3Q8:0-ginkgo-bioworks-holdings-inc-expected-to-post-a-loss-of-1-57-a-share-earnings-preview/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U00S8:0-ginkgo-bioworks-holdings-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios